Drugs & Aging

, Volume 31, Issue 5, pp 349–361 | Cite as

Pharmacologic Options in the Management of Upper Gastrointestinal Bleeding: Focus on the Elderly

Review Article

Abstract

Despite the major advances in the treatment of peptic ulcer disease, its complication in the elderly has increased. This is because of the increasing use of non-steroidal anti-inflammatory drugs, and the high prevalence of Helicobacter pylori infection. The presentation of peptic ulcers in the elderly patients can be subtle, and late presentation with upper gastrointestinal bleeding of peptic ulcers is not uncommon in the elderly population. The aim of this article is to review the current treatment options for upper gastrointestinal bleeding, and to discuss the place of drug therapy in both the acute and ongoing management of individual patients. Its focus will be on the benefits and risks of each option in the elderly. There is significant evidence to suggest that anti-secretory medications are useful in the treatment of peptic ulcers and associated complications in the elderly. Although a large number of studies have reported potential adverse effects of proton pump inhibitors, this evidence comes from retrospective observational studies, and such reports should be regarded with caution, and randomized controlled studies are required to confirm or refute these results. Nonetheless, it will be important to practice the appropriate use of acid suppression therapy, and identify which patients will gain maximum benefit from proton pump inhibitor therapy.

References

  1. 1.
    Bardhan KD, Cust G, Hinchliffe RF, et al. Changing pattern of admissions and operations for duodenal ulcer. Br J Surg. 1989;76:230–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002;50:460–4.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Newton JL. Improving the gastrointestinal tolerability of aspirin in older people. Clin Interv Aging. 2006;1:33–9.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med. 1992;116:636–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Goto H, Sugiyama S, Ohara A, et al. Age-associated decreases in prostaglandin contents in human gastric mucosa. Biochem Biophys Res Commun. 1992;186:1443–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Guslandi M, Pellegrini A, Sorghi M. Gastric mucosal defences in the elderly. Gerontology. 1999;45:206–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Kim SW, Parekh D, Townsend CM, Jr, et al. Effects of aging on duodenal bicarbonate secretion. Ann Surg. 1990;212:332–7 (discussion 337–8).Google Scholar
  8. 8.
    Brogna A, Ferrara R, Bucceri AM, et al. Influence of aging on gastrointestinal transit time: an ultrasonographic and radiologic study. Invest Radiol. 1999;34:357–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom: Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995;311:222–6.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Seinela L, Ahvenainen J. Peptic ulcer in the very old patients. Gerontology. 2000;46:271–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Kemppainen H, Raiha I, Sourander L. Clinical presentation of peptic ulcer in the elderly. Gerontology. 1997;43:283–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Pilotto A, Maggi S, Noale M, et al. Development and validation of a new questionnaire for the evaluation of upper gastrointestinal symptoms in the elderly population: a multicenter study. J Gerontol A Biol Sci Med Sci. 2010;65:174–8.PubMedCrossRefGoogle Scholar
  13. 13.
    de Manzoni G, Catalano F, Festini M, et al. Acute hemorrhage caused by duodenal ulcer: results of endoscopic treatment of the first bleeding episode and of recurrences. Ann Ital Chir. 2002;73:387–94 (discussion 394–6).Google Scholar
  14. 14.
    Carbonell N, Pauwels A, Serfaty L, et al. Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol. 2006;101:1211–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Coffin B, Pocard M, Panis Y, et al. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc. 2002;56:174–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Frossard JL, Spahr L, Queneau PE, et al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology. 2002;123:17–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Barkun AN, Bardou M, Martel M, et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc. 2010;72:1138–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Pateron D, Vicaut E, Debuc E, et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med. 2011;57:582–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med. 2007;356:1631–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(7):CD005415.Google Scholar
  21. 21.
    Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009;7:33–47 (quiz 1–2).Google Scholar
  22. 22.
    Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2013;6:CD007999.Google Scholar
  23. 23.
    Tsoi KK, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Aliment Pharmacol Ther. 2013;38:721–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994;331:717–27.PubMedCrossRefGoogle Scholar
  25. 25.
    Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs: Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991;337:85–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Visser LE, Graatsma HH, Stricker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol. 2002;53:183–8.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104–10.PubMedCrossRefGoogle Scholar
  28. 28.
    Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007;369:1621–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Sung JJ, Chan FK, Chen M, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011;60:1170–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Lau JY, Barkun A, Fan DM, et al. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013;381:2033–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745–54.PubMedCrossRefGoogle Scholar
  33. 33.
    Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004;20:1091–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study. Ital J Gastroenterol Hepatol. 1998;30:43–7.PubMedGoogle Scholar
  35. 35.
    Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut. 2002;51:329–35.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.Google Scholar
  38. 38.
    Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs: Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719–26.PubMedCrossRefGoogle Scholar
  39. 39.
    Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Stupnicki T, Dietrich K, Gonzalez-Carro P, et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion. 2003;68:198–208.PubMedCrossRefGoogle Scholar
  41. 41.
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138:82–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Wang X, Tian HJ, Yang HK, et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23:876–80.PubMedCrossRefGoogle Scholar
  46. 46.
    Pilotto A. Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies. Drugs Aging. 2001;18:487–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Pilotto A, Franceschi M, Di Mario F, et al. The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease. Gerontology. 1998;44:153–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Salles N, Megraud F. Current management of Helicobacter pylori infections in the elderly. Expert Rev Anti Infect Ther. 2007;5:845–56.PubMedCrossRefGoogle Scholar
  49. 49.
    Pilotto A, Franceschi M, Leandro G, et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Aliment Pharmacol Ther. 2001;15:1031–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Pilotto A, Franceschi M, Perri F, et al. Treatment options for Helicobacter pylori infection in the elderly. Aging Health. 2006;2:661.CrossRefGoogle Scholar
  51. 51.
    Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.PubMedCrossRefGoogle Scholar
  52. 52.
    Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med. 1999;159:2312–6.PubMedGoogle Scholar
  53. 53.
    Ishihara M, Ito M. Influence of aging on gastric ulcer healing activities of cimetidine and omeprazole. Eur J Pharmacol. 2002;444:209–15.PubMedCrossRefGoogle Scholar
  54. 54.
    Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care. 2000;6:S491–505.PubMedGoogle Scholar
  55. 55.
    Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173:518–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21:1203–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103:207–11.PubMedCrossRefGoogle Scholar
  58. 58.
    Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993;41:940–6.PubMedGoogle Scholar
  59. 59.
    Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006;23:3–10.PubMedCrossRefGoogle Scholar
  60. 60.
    Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56 (quiz 2057).Google Scholar
  61. 61.
    Janarthanan S, Ditah I, Kutait A. A meta-analysis of 16 observational studies on proton pump inhibitor use and risk of Clostridium difficile associated diarrhea. Am J Gastroenterol. 2010;105:S139.CrossRefGoogle Scholar
  62. 62.
    Shukla S, Shukla A, Guha S. Use of proton pump inhibitors and risk of Clostridium difficile-associated diarrhea: a meta-analysis. Gastroenterology. 2010;138:209.Google Scholar
  63. 63.
    Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:225–33.PubMedCrossRefGoogle Scholar
  64. 64.
    Thomson AB, Sauve MD, Kassam N, et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323–30.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39:54–9.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Altman KW, Waltonen JD, Hammer ND, et al. Proton pump (H+/K+-ATPase) expression in human laryngeal seromucinous glands. Otolaryngol Head Neck Surg. 2005;133:718–24.PubMedCrossRefGoogle Scholar
  67. 67.
    Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31:1165–77.PubMedCrossRefGoogle Scholar
  68. 68.
    Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183:310–9.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5:337–44.PubMedCrossRefGoogle Scholar
  70. 70.
    O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.PubMedCrossRefGoogle Scholar
  71. 71.
    Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106:1209–18 (quiz 1219).Google Scholar
  73. 73.
    Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48:768–76.PubMedCrossRefGoogle Scholar
  74. 74.
    Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23:794–800.PubMedCrossRefGoogle Scholar
  75. 75.
    Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf. 2013;12:709–16.PubMedCrossRefGoogle Scholar
  76. 76.
    Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14:288–92.PubMedCrossRefGoogle Scholar
  77. 77.
    Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999;19:357–77.PubMedCrossRefGoogle Scholar
  78. 78.
    Saltzman JR, Kemp JA, Golner BB, et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. J Am Coll Nutr. 1994;13:584–91.PubMedCrossRefGoogle Scholar
  79. 79.
    Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120:211–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110–21.PubMedCrossRefGoogle Scholar
  81. 81.
    Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9:162–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Dharmarajan TS, Norkus EP. Does long-term PPI use result in vitamin B12 deficiency in elderly individuals? Nat Clin Pract Gastroenterol Hepatol. 2008;5:604–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA. 1996;275:308–14.PubMedCrossRefGoogle Scholar
  84. 84.
    Messori A, Trippoli S, Vaiani M, et al. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321:1103–6.PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet. 2009;374:1196–208.PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Ornstein SM, Nietert PJ, Jenkins RG, et al. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J Am Board Fam Med. 2013;26:518–24.PubMedCrossRefGoogle Scholar
  87. 87.
    Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–84.PubMedCrossRefGoogle Scholar
  88. 88.
    Sergi G, De Rui M, Sarti S, et al. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28:509–18.PubMedCrossRefGoogle Scholar
  89. 89.
    Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096–9.PubMedCentralPubMedCrossRefGoogle Scholar
  90. 90.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.PubMedCrossRefGoogle Scholar
  91. 91.
    Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Simonson W, Feinberg JL. Medication-related problems in the elderly: defining the issues and identifying solutions. Drugs Aging. 2005;22:559–69.PubMedCrossRefGoogle Scholar
  93. 93.
    Department of Health. Medicines and older people: implementing medicines-related aspects of the NSF for older people; 2001. http://www.hcsu.org.uk/index.php?option=com_docman&task=doc_download&gid=322%20. Accessed Feb 2014.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Institute of Digestive DiseasesThe Chinese University of Hong Kong, Prince of Wales HospitalShatinHong Kong

Personalised recommendations